Navigation Links
James Thomson receives 2008 Massry Prize honoring stem cell researchers
Date:12/18/2008

008 prize that bears his name honors three individuals who were instrumental in discovering that cells from adult tissue such as skin could be reprogrammed back to an embryonic state. He calls the discovery "an amazing advance that opens broad new horizons for the application of stem cell technology."

Massry states that techniques pioneered by this year's winners are being refined worldwide to enhance their safety and applicability, and that experiments in animal models of transplantation therapy already have shown that iPS cells can provide tissue that is genetically matched to the recipient and not a target for immune rejection. Further, scientists already are using the technology to make patient-specific stem cell lines from individuals suffering from genetic diseases, enabling them to study how these diseases develop and to identify new therapeutic interventions.


'/>"/>

Contact: Terry Devitt
trdevitt@wisc.edu
608-262-8282
University of Wisconsin-Madison
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. NASA scientist James Hansen to speak at July 11 conference on Rejuvenating Public Sector Science
2. James Briscoe awarded 2008 EMBO Gold Medal
3. Rices James Tour wins Feynman Prize
4. Rutgers Genetics receives $7.8 million for autism research
5. Herr receives Heinz Award for Technology, the Economy and Employment
6. UCI receives $5M from Edwards Lifesciences
7. Yu receives research funding from the Wallace H. Coulter Foundation
8. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
9. UC Riverside biologist receives prestigious MacArthur Fellowship
10. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
11. Penn biochemist receives NIH New Innovators Award
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):White, but not pure 2White, but not pure 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6The Lupus Foundation of America Applauds New Legislation that Caps Out of Pocket Drug Costs 53992 1The Lupus Foundation of America Applauds New Legislation that Caps Out of Pocket Drug Costs 53992 2Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 1Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 2Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 3Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 4Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 5Duane Reade Holdings Inc Announces Closing of Offering of 24300 Million of 11 75 25 Senior Secured Notes Due 2015 53986 6WebMD to Present at the Canaccord Adams 29th Annual Global Growth Conference 53982 1
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4